Clinical application of tissue inhibitor of metalloproteinases-l in assessment of liver fibrosis
Objective To evaluate the clinical value of TIMP-1 in diagnosis of liver fibrosis. Methods Patients with CHB were divided into mild liver fibrosis group (S0-S1,175) and significant liver fibrosis group(S2-S4,110), according to pathological diagnosis. The diagnostic capacity of CTGF was assessed by comparing the area under receiver operating characteristic(AUC) with a panel of fibrosis markers. Resolts Serum level of TIMP-1 in control group, S0-S1 ,S2-S4 was 146. 6±29. 2,161. 2±43.2,221.6±93.8 μg/L,respectively. The level of TIMP-1 in S2-S4 group was significantly higher than that of S0-S1 group(t=5. 32,P<0.01) and that of control group(i=4. 98,P<0. 01). The area ROC of TIMP-1 was 0. 841(95% confidence interval,0. 762～0. 920) in distinguishing mild fibrosis from significant fibrosis, which was highest among five markers. When cutoff value of TIMP-1 was 10.3 μg/L,the sensitivity and specification was 70.5%,82. 4% which were higher than that of HA{75. 65％,72. 5%}, PC Ⅲ (70. 5%, 76.5%),CIY(63. 6%,78. 4%),LN(79. 5^,64.7%),APRI(86. 354,66. 154) for assessing liver fibrosis. Concln-atom Serum TIMP-1 has higher sensitivity, specificity in assessment of liver fibrosis, which may be a valuable marker for assessing liver fibrosis.
Tissue Inhibitor of Metalloproteinase-1diagnostic useLiver Cirrhosisdiagnosis
NETL
NSTL
万方数据
维普
